Merve Okuyan

Dr. Merve Okuyan

Nuclear Medicine, Recep Tayyip Erdoğan University, Rize, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2024 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
EŞErtan Şahin
Ertan Şahin
TKTulay Kus
Tulay Kus
AAAlper Aytekin
Alper Aytekin
EUEvren Uzun
Evren Uzun
UEUmut Elboga
Umut Elboga
UCUfuk Cimen
Ufuk Cimen
Accurate staging of invasive lobular carcinoma (ILC), a subtype of breast cancer, is vital for effective clinical management. Although 18F-FDG PET/CT is a commonly used tool, its efficacy varies across different histologic subtypes. To mitigate this challenge, our investigation delves into the potential utility of 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT as an alternative for staging ILC, aiming to address a significant research gap using a more expansive patient cohort than the smaller samples commonly found in the existing literature. Methods: In this retrospective analysis, women diagnosed with primary ILC of the breast underwent both 18F-FDG PET/CT and 68Ga-FAPI PET/CT. Both modalities were compared across all lesion locations with the used reference standard. The interval between scans was 1 wk, without any intervening treatments. Lesions were categorized visually, and tracer activity was analyzed using SUVmax, tumor-to-background uptake ratio, and uptake ratios. Both modalities were compared across various parameters, and statistical analysis was performed using SPSS 22.0. A P value of less than 0.05 was chosen to determine statistical significance. Results: The study included 23 female ILC patients (mean age, 51 y) with hormone-positive, human epidermal growth factor receptor type 2–negative tumors. Most (65%) had the luminal A subtype. 68Ga-FAPI PET/CT outperformed 18F-FDG PET/CT, with higher tumoral activity and tumor-to-background uptake ratios (P < 0.001). Primary tumors showed significantly increased uptake with 68Ga-FAPI PET/CT (P < 0.001), detecting additional foci, including multicentric cancer. Axillary lymph node metastases were more frequent and had higher uptake values with 68Ga-FAPI PET/CT (P = 0.012). Moreover, 68Ga-FAPI PET/CT identified more lesions, including bone and liver metastases. Pathologic features did not significantly correlate with imaging modalities, but a positive correlation was observed between peritumoral lymphocyte ratio and 68Ga-FAPI PET/CT–to–18F-FDG PET/CT uptake ratios (P = 0.026). Conclusion: This study underscores 68Ga-FAPI PET/CT’s superiority over 18F-FDG PET/CT for ILC. 68Ga-FAPI PET/CT excels in detecting primary breast masses, axillary lymph nodes, and distant metastases; can complement 18F-FDG PET/CT in ILC; and holds potential as an alternative imaging method in future studies. Visual Abstract

11 April 2022 in Molecular Imaging and Biology
Verified
Journal Article
Closed access
PDF file
UEUmut Elboga
Umut Elboga
ESErtan Sahin
Ertan Sahin
TKTulay Kus
Tulay Kus
YCYusuf Burak Cayirli
Yusuf Burak Cayirli
GAGokmen Aktas
Gokmen Aktas
YCYusuf Zeki Celen
Yusuf Zeki Celen

1 February 2022 in Tomography
Verified
Journal Article
Open access
PDF file
UEUmut Elboga
Umut Elboga
ESErtan Sahin
Ertan Sahin
YCYusuf Burak Cayirli
Yusuf Burak Cayirli
Merve OkuyanMerve Okuyan
Merve Okuyan
GAGokmen Aktas
Gokmen Aktas
YCYusuf Zeki Celen
Yusuf Zeki Celen
Objective: In this study, we aimed to compare [68Ga]FAPI PET/CT and [18F]FDG PET/CT imaging to detect lesions in multiple myeloma. Methods: A total of 14 patients with multiple myeloma who underwent [68Ga]FAPI PET/CT and [18F]FDG PET/CT imaging were included in this retrospective study. SUVmax values of [68Ga]FAPI and [18F]FDG were compared according to lesion locations. Also, lesion localization ability of both imaging methods was compared on the patient basis. Results: In 4 of 14 patients, [68Ga]FAPI PET/CT and [18F]FDG PET/CT have not detected any bone lesions. In 8 of the remaining 10 patients [18F]FDG PET/CT detected bone lesions but in this group, 6 patients showed more higher SUVmax values than [18F]FDG PET/CT in [68Ga]FAPI PET/CT.In contrast, 2 of 8 patients showed more higher SUVmax values than [68Ga]FAPI PET/CT in [18F]FDG PET/CT. Moreover, [68Ga]FAPI PET/CT detected bone lesions in two patients, which werenot detected by [18F]FDG PET/CT. Also, in five patients, [68Ga]FAPI PET/CT showed more bone lesions in comparison with[18F]FDG PET/CT. Only one patient, [18F]FDG PET/CT showed more bone lesions. Three extramedullary involvements were observed in the following locations: lung, presacral lymph node, and soft tissue mass lateral to the right maxillary sinus. Among these involvements, higher SUVmax values were observed in the lung and presacral lymph node with [68Ga]FAPI compared to [18F]FDG. However, the soft tissue mass showed a higher SUVmax value in [18F]FDG than [68Ga]FAPI. Conclusions: No significant superiority was observed in [68Ga]FAPI PET/CT over [18F]FDG PET/CT in patients with MM. However, [68Ga]FAPI PET/CT can be utilized as a complementary imaging method to [18F]FDG PET/CT in some settings, especially in low-[18F]FDG affinity and inconclusive cases. Considering the favorable aspects of [68Ga]FAPI PET/CT in MM, such as low background activity, absence of non-specific bone marrow, and physiological brain involvement, further studies with a larger sample size should be conducted.

1 December 2024 in Current Radiopharmaceuticals
Verified
Journal Article
Closed access
PDF file
ESErtan Sahin
Ertan Sahin
UEUmut Elboga
Umut Elboga
UCUfuk Cimen
Ufuk Cimen
Merve OkuyanMerve Okuyan
Merve Okuyan
YCYusuf Burak Cayirli
Yusuf Burak Cayirli
Objective: This study aimed to evaluate the therapeutic efficacy and safety of 177Lutetium-Prostate Specific Membrane Antigen (177Lu-PSMA-617) radioligand treatment (RLT) in metastatic castration-resistant prostate cancer (mCRPC) patients with aged older than 75 years. Methods: A total of 37 patients with mCRPC aged older than 75 years treated with 177Lu- PSMA-617 were included in this study. Pre-therapy and post-therapy biochemical, metabolic, and clinical response results and Hb, TLC, platelet, serum creatinine and bilirubin levels were checked to evaluate the therapeutic efficacy and toxicity profile. The Common Terminology Criteria for Adverse Events was used for grading adverse events caused by 177Lu-PSMA-617 treatment. Results: The mean age of the patients included in the study was 79.8±2.9 (76-92). The number of 177Lu-PSMA-617 treatment cycles ranged from two to four, and the mean administered radioactivity dose was 5.6±0.8 GBq per cycle. Partial biochemical response (PR) and partial metabolic response (PMR) were observed in 11 (29.7%) and 15 (40.6%) patients after treatment, respectively. Although improvement in ECOG scores was observed in 5 (13.5%) patients after treatment, it was not statistically significant. Grade 2 and 3 Hb toxicity was observed in 10 (27%) and 2 (5.4%) patients, respectively. Grade 2 leukocytopenia in six patients, Grade 1 thrombocytopenia in six patients, and Grade 2 serum creatinine toxicity in five patients were seen after the treatment. On the other hand, no patients developed liver toxicity and grade 3 or 4 leukocytopenia, thrombocytopenia or creatinine toxicity. Conclusion: 177Lu-PSMA-617 treatment was a safe and effective treatment option for properly selected elderly mCRPC patients.

6 March 2026 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
PDF file
Seçkin BilgiçSeçkin Bilgiç
Seçkin Bilgiç
Merve OkuyanMerve Okuyan
Merve Okuyan
EIEfrah İbRahim
Efrah İbRahim
Metabolically Silent Diffuse Hepatic Involvement in Multiple Myeloma: An 18F-FDG-PET/CT Pitfall - Molecular Imaging and Radionuclide Therapy

1 September 2023
Verified
Journal Article
Closed access
UEUmut Elboga
Umut Elboga
ESErtan Sahin
Ertan Sahin
TKTulay Kus
Tulay Kus
Merve OkuyanMerve Okuyan
Merve Okuyan
YCYusuf Burak Cayirli
Yusuf Burak Cayirli
YCYusuf Zeki Celen
Yusuf Zeki Celen